News

Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination therapy BREZTRI AEROSPHERE ...
The single-inhaler demonstrated a meaningful improvement in lung function in the Phase III KALOS and LOGOS studies.
AstraZeneca has announced the Positive high-level results from the Phase III KALOS and LOGOS trials in patients with ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple ...
In a stunning collapse, the Bucks let a 7-point lead slip away in the final 30 seconds of Game 5, ending their playoff run in ...
AstraZeneca’s fixed-dose triple-combination therapy, Breztri meets primary endpoints in KALOS & LOGOS phase III trials in asthma: Cambridge, UK Saturday, May 3, 2025, 10:00 Hrs ...
Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination therapy BREZTRI AEROSPHERE ...
In a stunning collapse, the Bucks let a 7-point lead slip away in the final 30 seconds of Game 5, ending their playoff run in ...
AstraZeneca has taken a key step in advancing Breztri Aerosphere toward a potential label expansion and achieving its goal of ...
AstraZeneca announced on Friday that its inhaled triple-combination therapy ‘Breztri Aerosphere’ met all primary endpoints in ...